Nuove strategie di impiego dei fattori di crescita mielopoietici

Translated title of the contribution: New strategies for use of myelopoietic growth factors

Marco Danova, Palma Pugliese, Alberto Riccardi

Research output: Contribution to journalArticle

Abstract

The myelopoietic growth factors, in particular G-CSF and GM-CSF have been available for clinical use for only a few years but they have already profoundly affected the management of chemotherapy-induced neutropenia, the use of dose-intensive chemotherapy regimens, and the practice and safety of autologous stem cell transplantation. While these growth factors have rapidly been introduced as routine agents in the management of cancer patients, they have continued to generate a considerable amount of basic research on the biology of hematopoiesis as well as on the growth regulation of normal and tumor cells. One attractive possibility offered by growth factors is to protect hemopoietic stem and progenitor cells from the toxic effects of chemotherapy, while not diminishing its anti-tumor action. Any means of preferentially and reversibly suppressing the proliferation of normal hemopoietic stem and progenitor cell while leaving unmodified the proliferation of tumor cells and their susceptibility to chemotherapy, could potentially optimize treatment efficacy. In the present paper, we have briefly discussed the possibility to use the myeloid growth factors as myeloprotective agents in the context of drug-intensified chemotherapy on the basis of the results obtained during some clinical trials recently conducted in patients with advanced cancer.

Original languageItalian
JournalTumori
Volume83
Issue number5 SUPPL.
Publication statusPublished - Sep 1997

Fingerprint

Intercellular Signaling Peptides and Proteins
Drug Therapy
Stem Cells
Neoplasms
Granulocyte-Macrophage Colony-Stimulating Factor
Poisons
Hematopoiesis
Stem Cell Transplantation
Granulocyte Colony-Stimulating Factor
Neutropenia
Cell Proliferation
Clinical Trials
Safety
Growth
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research

Cite this

Nuove strategie di impiego dei fattori di crescita mielopoietici. / Danova, Marco; Pugliese, Palma; Riccardi, Alberto.

In: Tumori, Vol. 83, No. 5 SUPPL., 09.1997.

Research output: Contribution to journalArticle

Danova, M, Pugliese, P & Riccardi, A 1997, 'Nuove strategie di impiego dei fattori di crescita mielopoietici', Tumori, vol. 83, no. 5 SUPPL..
Danova, Marco ; Pugliese, Palma ; Riccardi, Alberto. / Nuove strategie di impiego dei fattori di crescita mielopoietici. In: Tumori. 1997 ; Vol. 83, No. 5 SUPPL.
@article{6fc02ab606d2400d93807ebf7a056f19,
title = "Nuove strategie di impiego dei fattori di crescita mielopoietici",
abstract = "The myelopoietic growth factors, in particular G-CSF and GM-CSF have been available for clinical use for only a few years but they have already profoundly affected the management of chemotherapy-induced neutropenia, the use of dose-intensive chemotherapy regimens, and the practice and safety of autologous stem cell transplantation. While these growth factors have rapidly been introduced as routine agents in the management of cancer patients, they have continued to generate a considerable amount of basic research on the biology of hematopoiesis as well as on the growth regulation of normal and tumor cells. One attractive possibility offered by growth factors is to protect hemopoietic stem and progenitor cells from the toxic effects of chemotherapy, while not diminishing its anti-tumor action. Any means of preferentially and reversibly suppressing the proliferation of normal hemopoietic stem and progenitor cell while leaving unmodified the proliferation of tumor cells and their susceptibility to chemotherapy, could potentially optimize treatment efficacy. In the present paper, we have briefly discussed the possibility to use the myeloid growth factors as myeloprotective agents in the context of drug-intensified chemotherapy on the basis of the results obtained during some clinical trials recently conducted in patients with advanced cancer.",
keywords = "G-CSF, GM-CSF, Hemopoietic cell kinetics, Myeloid growth factors, Stem cell exhaustion",
author = "Marco Danova and Palma Pugliese and Alberto Riccardi",
year = "1997",
month = "9",
language = "Italian",
volume = "83",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "5 SUPPL.",

}

TY - JOUR

T1 - Nuove strategie di impiego dei fattori di crescita mielopoietici

AU - Danova, Marco

AU - Pugliese, Palma

AU - Riccardi, Alberto

PY - 1997/9

Y1 - 1997/9

N2 - The myelopoietic growth factors, in particular G-CSF and GM-CSF have been available for clinical use for only a few years but they have already profoundly affected the management of chemotherapy-induced neutropenia, the use of dose-intensive chemotherapy regimens, and the practice and safety of autologous stem cell transplantation. While these growth factors have rapidly been introduced as routine agents in the management of cancer patients, they have continued to generate a considerable amount of basic research on the biology of hematopoiesis as well as on the growth regulation of normal and tumor cells. One attractive possibility offered by growth factors is to protect hemopoietic stem and progenitor cells from the toxic effects of chemotherapy, while not diminishing its anti-tumor action. Any means of preferentially and reversibly suppressing the proliferation of normal hemopoietic stem and progenitor cell while leaving unmodified the proliferation of tumor cells and their susceptibility to chemotherapy, could potentially optimize treatment efficacy. In the present paper, we have briefly discussed the possibility to use the myeloid growth factors as myeloprotective agents in the context of drug-intensified chemotherapy on the basis of the results obtained during some clinical trials recently conducted in patients with advanced cancer.

AB - The myelopoietic growth factors, in particular G-CSF and GM-CSF have been available for clinical use for only a few years but they have already profoundly affected the management of chemotherapy-induced neutropenia, the use of dose-intensive chemotherapy regimens, and the practice and safety of autologous stem cell transplantation. While these growth factors have rapidly been introduced as routine agents in the management of cancer patients, they have continued to generate a considerable amount of basic research on the biology of hematopoiesis as well as on the growth regulation of normal and tumor cells. One attractive possibility offered by growth factors is to protect hemopoietic stem and progenitor cells from the toxic effects of chemotherapy, while not diminishing its anti-tumor action. Any means of preferentially and reversibly suppressing the proliferation of normal hemopoietic stem and progenitor cell while leaving unmodified the proliferation of tumor cells and their susceptibility to chemotherapy, could potentially optimize treatment efficacy. In the present paper, we have briefly discussed the possibility to use the myeloid growth factors as myeloprotective agents in the context of drug-intensified chemotherapy on the basis of the results obtained during some clinical trials recently conducted in patients with advanced cancer.

KW - G-CSF

KW - GM-CSF

KW - Hemopoietic cell kinetics

KW - Myeloid growth factors

KW - Stem cell exhaustion

UR - http://www.scopus.com/inward/record.url?scp=0031408571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031408571&partnerID=8YFLogxK

M3 - Articolo

C2 - 9446256

AN - SCOPUS:0031408571

VL - 83

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 5 SUPPL.

ER -